104 related articles for article (PubMed ID: 7167013)
1. [Circulating anti-coagulant anti-prothrombinase and thrombosis: an association found in 5 out of 9 case reports].
Goudemand J; Watel A; Ecroignard M; Marey A; Parquet A; Mazurier C; Dufay C; Cosson A
LARC Med; 1982 May; 2(5):371-6. PubMed ID: 7167013
[No Abstract] [Full Text] [Related]
2. [Anticoagulants with antithrombinase activity in systemic lupus erythematosus (author's transl)].
Jungers P; Dougados M; Ganzegel C; Kremp O; Jacques C; Noel LH; Josso F
Nephrologie; 1980; 1(2):67-8. PubMed ID: 7301023
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of the prothrombinase complex: factor Va alters macromolecular recognition of a tick anticoagulant peptide mutant by factor Xa.
Betz A; Vlasuk GP; Bergum PW; Krishnaswamy S
Biochemistry; 1997 Jan; 36(1):181-91. PubMed ID: 8993332
[TBL] [Abstract][Full Text] [Related]
4. A new type of antithrombotic agent: action of antithrombin III - factor Xa complex.
Bajwa SS
Proc West Pharmacol Soc; 1981; 24():275-9. PubMed ID: 7255468
[No Abstract] [Full Text] [Related]
5. [Lupus anticoagulant screening: comparison of 5 tests (author's transl)].
Follea G; Ffrench P; Trzeciak MC; Dechavanne M
Nouv Rev Fr Hematol (1978); 1981; 23(4):203-7. PubMed ID: 7312614
[TBL] [Abstract][Full Text] [Related]
6. Increased prothrombinase binding sites in unstimulated platelets from a protein C deficient patient.
Scully MF; Ellis V; Melissari E; Kakkar VV
Thromb Haemost; 1984 Jul; 51(3):407. PubMed ID: 6548586
[No Abstract] [Full Text] [Related]
7. [Coagulation factors before and after peritoneal dialysis in chronic uremia].
Mingers A; Ströder J; Pavel W; Göltner E; Scheitza E
Z Gesamte Exp Med Einschl Exp Chir; 1969; 150(2):101-19. PubMed ID: 5803102
[No Abstract] [Full Text] [Related]
8. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
9. SV-IV Peptide1-16 reduces coagulant power in normal Factor V and Factor V Leiden.
Di Micco B; Lepretti M; Rota L; Quaglia I; Ferrazzi P; Di Micco G; Di Micco P
J Transl Med; 2007 Dec; 5():69. PubMed ID: 18154667
[TBL] [Abstract][Full Text] [Related]
10. [Biological study of the action of pentosan polysulfate in severe burn patients].
Freyburger G; Vergnes C; Hourdille R; Boisseau MR; Sanchéz R; Cutillas M; Perro G
Ann Chir; 1984 Apr; 38(3):247-52. PubMed ID: 6203465
[No Abstract] [Full Text] [Related]
11. Factor Xa inhibitors: today and beyond.
Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
[TBL] [Abstract][Full Text] [Related]
12. The nature of the binding for prothrombinase at the platelet surface as revealed by lipolytic enzymes.
Bevers EM; Comfurius P; Zwaal RF
Eur J Biochem; 1982 Feb; 122(1):81-5. PubMed ID: 7060571
[TBL] [Abstract][Full Text] [Related]
13. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
[TBL] [Abstract][Full Text] [Related]
14. Acquired circulating anticoagulant with anti-factor V activity in AIDS: first case report.
Denis A; Baudeau C; Verdy E; Couderc R; Rondeau E; Sraer JD
Nouv Rev Fr Hematol (1978); 1995; 37(2):165-9. PubMed ID: 7644356
[TBL] [Abstract][Full Text] [Related]
15. Purification and characterization of an anticoagulant from the salivary glands of the ixodid tick Rhipicephalus appendiculatus.
Limo MK; Voigt WP; Tumbo-Oeri AG; Njogu RM; ole-MoiYoi OK
Exp Parasitol; 1991 May; 72(4):418-29. PubMed ID: 2026216
[TBL] [Abstract][Full Text] [Related]
16. [Role of the liver in producing heat-stable antifactor Xa].
Galian SL
Biull Eksp Biol Med; 1980 Jul; 89(7):7-9. PubMed ID: 7407374
[TBL] [Abstract][Full Text] [Related]
17. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
18. [Hereditary factor V deficiency and factor V inhibitor without bleeding. Rare causes of pathological screening tests of coagulation].
Borucki K; Töpfer G; Hartung KJ; Lutze G
Hamostaseologie; 2007 Aug; 27(3):188-90. PubMed ID: 17694226
[TBL] [Abstract][Full Text] [Related]
19. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
Camire RM; Kalafatis M; Tracy PB
Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
